CP

Caligan Partners Portfolio holdings

AUM $1.09B
1-Year Est. Return 521.75%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+521.75%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$721M
AUM Growth
+$206M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
21
New
Increased
Reduced
Closed

Top Buys

1
+$45.2M
2
+$16.7M
3
+$16.3M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$15.7M
5
AVTX icon
Avalo Therapeutics
AVTX
+$7.17M

Top Sells

1
+$136M
2
+$28.7M
3
+$13.6M
4
YMAB
Y-mAbs Therapeutics
YMAB
+$10.6M
5
RZLT icon
Rezolute
RZLT
+$6.88M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$2.99B
$185M 25.62%
8,118,892
ABVX
2
Abivax
ABVX
$9.23B
$123M 17.1%
1,451,924
-222,476
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.28B
$105M 14.59%
2,772,654
+755,302
EXEL icon
4
Exelixis
EXEL
$10.8B
$63M 8.74%
1,525,730
RVMD icon
5
Revolution Medicines
RVMD
$19.6B
$49.7M 6.9%
1,064,249
+427,414
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.65B
$45.4M 6.3%
1,131,205
+59,947
ADMA icon
7
ADMA Biologics
ADMA
$3.94B
$38.7M 5.36%
+2,636,609
EOLS icon
8
Evolus
EOLS
$362M
$25.4M 3.53%
4,138,943
+796,973
MRUS
9
DELISTED
Merus
MRUS
$20.4M 2.83%
216,954
-440,045
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.33B
$17.8M 2.48%
+444,565
ANIK icon
11
Anika Therapeutics
ANIK
$207M
$13.5M 1.87%
1,435,130
AVTX icon
12
Avalo Therapeutics
AVTX
$340M
$10.6M 1.47%
+833,333
TYRA icon
13
Tyra Biosciences
TYRA
$1.88B
$9.75M 1.35%
696,825
+506,875
INBX icon
14
Inhibrx
INBX
$1.09B
$7.96M 1.1%
+236,383
VRCA icon
15
Verrica Pharmaceuticals
VRCA
$85.2M
$3.98M 0.55%
923,910
-2
AURA icon
16
Aura Biosciences
AURA
$391M
$1.4M 0.19%
227,174
+27,174
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.13B
– –
-638,908
RZLT icon
18
Rezolute
RZLT
$314M
– –
-1,543,014
SLS icon
19
SELLAS Life Sciences
SLS
$943M
– –
0
VRNA
20
DELISTED
Verona Pharma
VRNA
– –
-1,436,878
YMAB
21
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-2,342,609